Jeffrey Venstrom

Jeffrey Venstrom, MD, is a physician-scientist and biotechnology executive with more than two decades of experience advancing oncology therapeutics, precision medicine, and cancer diagnostics. His career spans academic medicine and global biopharmaceutical and diagnostics organizations, with a focus on translating scientific discoveries into clinically meaningful innovations that improve patient outcomes.

Dr. Venstrom is Chief Medical Officer of ClearNote Health, where he leads medical affairs, lab operations, clinical operations, clinical development and real-world evidence generation to advance blood-based early cancer detection. Previously, he served as Global Head of Diagnostics at Eli Lilly and Company and Chief Medical Officer of GRAIL, helping advance multi-cancer early detection. At Roche/Genentech and Foundation Medicine, he held senior leadership roles in biomarker development, clinical development, medical affairs, and precision oncology, contributing to the development and clinical adoption of genomic profiling and companion diagnostics.

Earlier in his career, Dr. Venstrom was the Krishnamurthi Endowed Chair in Hematologic Malignancies at the University of California, San Francisco, where he cared for patients with cancer and led translational research. He completed his internal medicine residency at The Johns Hopkins Hospital and his oncology and cancer immunology training at Memorial Sloan Kettering Cancer Center, with additional research training at the National Institutes of Health. He earned his medical degree and undergraduate degree from Vanderbilt University. His work is driven by a commitment to shifting cancer care toward earlier detection, more personalized treatment, and evidence-based innovations that deliver meaningful benefits for patients.